Sangamo BioSciences Announces Presentation at the JMP Securities Research ... ( RICHMOND Calif. May 13 /- Sangamo B...)

Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference

Date:5/13/2009

RICHMOND, Calif., May 13 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 10:00 am PT on Wednesday, May 20, 2009 at the Eighth Annual JMP Securities Conference which will be held in San Francisco.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo

Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Sangamo BioSciences to Present at the ThinkEquity Partners Growth Conference
2. Sangamo BioSciences Provides Update on Companys Accomplishments in 2007 and 2008 Objectives
3. Sangamo BioSciences Reports First Quarter 2009 Financial Results
4. Akers Biosciences, Inc. ABI or the Company Receipt of Further United States Military Contracts
5. Pressure BioSciences to Present at the Rodman & Renshaw BioFin 9th Annual Healthcare Conference in New York City on November 5th
6. Neurocrine Biosciences to Present at the CIBC World Markets 18th Annual Healthcare Conference
7. Pressure BioSciences, Inc. to Discuss Third Quarter Financial Results and Provide Business Update
8. Monogram Biosciences to Present at The Lazard Capital Markets Fourth Annual Healthcare Conference
9. Anaptys Biosciences Raises Over $33 Million in Series B Financing
10. YM BIOSCIENCES REPORTS FIRST QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS
11. Pressure BioSciences, Inc. Reports Third Quarter 2007 Financial Results and Provides Business Update

Post Your Comments:

(Date:5/18/2013)... California (PRWEB) May 18, 2013 Online watch ... be Rolex watch owners at a fraction of ... of luxury timepieces in the world, buyers are urged to ... compared to buying a Rolex watch from a brick-and-mortar store, ... owned Rolex watches priced at unbelievable rates. Although some ...

(Date:5/18/2013)... Thompson HealthDay Reporter , , FRIDAY, May 17 ... the latest edition of what is considered the "bible" ... many changes continues. "This is unprecedented, the amount ... Lieberman, president-elect of the American Psychiatric Association (APA). "It,s ... it is. You have to evaluate it and then ...

(Date:5/18/2013)... (HealthDay News) -- Just a few extra cups of ... an autoimmune liver disease known as primary sclerosing cholangitis ... Mayo Clinic in Rochester, Minn., found that drinking coffee ... disease, which can lead to cirrhosis of the liver, ... not prove a cause-and-effect relationship. "While rare, ...

(Date:5/18/2013)... The use of a smartphone application significantly ... new research presented today at Digestive Disease Week ... advance of the procedure, includes dietary restrictions and ... at strict intervals. The better the preparation, the ... and precancerous polyps in the colon. The study, ...

(Date:5/18/2013)... ROCHESTER, Minn. -- Regular consumption of coffee is ... cholangitis (PSC), an autoimmune liver disease, Mayo Clinic ... the Digestive Disease Week 2013 conference in Orlando, ... of the bile ducts that results in inflammation ... of the liver, liver failure and biliary cancer. ...

Breaking Medicine News(10 mins):Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2 Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 2 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 3 Health News:Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy 4 Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2 Health News:New smartphone application improves colonoscopy preparation 2

[0] Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet [0] Latest Edition of Psychiatry's 'Bible' Launched Amid Controversy [0] Study Links Coffee to Lower Risk for Rare Liver Disease [0] New smartphone application improves colonoscopy preparation [0] Consuming coffee linked to lower risk of detrimental liver disease, Mayo Clinic finds

... - Exclusive, multi-year contract executed by Intercell and ... First sales of IXIARO under this military contract ... ICLL; OTC Bulletin Board: INRLY) announced today that ... contract with the Defense Logistics Agency (DLA), Defense ...

... Sunday, individuals all over the nation will be celebrating a ... life: their mothers. While people in the United States turn ... (IBMP) hopes to inspire some to also think of mothers ... the United States send their breast milk to infants in ...

... may be used someday against Parkinson,s, too, expert suggests, , , ... to lend a hand in the death of brain cells ... according to a newly published study. , ... normally guides molecules in and out of cells, but it ...

... and recovery fairly quick , , FRIDAY, May 8 (HealthDay News) ... from over, with hundreds of new cases being reported each day, ... issue that,s been concerning me, that has to do with a ... over," Dr. Richard Besser, acting director of the U.S. Centers for ...

... Almost Family, Inc. (Nasdaq: AFAM ), a ... that William Yarmuth, President and Chief Executive Officer, and Steve ... to present at two upcoming investor conferences. The first ... 2009 Growth Stock Conference at the Four Seasons Hotel in ...

... ANN ARBOR, Mich., May 8 Thomson Reuters on ... hospital system for significantly improving the quality and managing ... plans and Tallahassee Memorial HealthCare are overall winners of ... hospitals and healthcare payers that use data analytics to ...

Intercell Executes Multi-Year Contract for Supply of IXIARO(R) to the United States Military International Breast Milk Project Helps Mothers Worldwide Protein Might Mute Effects of Methamphetamine As Swine Flu Cases Mount, CDC Says U.S. Hasn't 'Dodged a Bullet'Almost Family to Present at Two Upcoming Conferences Thomson Reuters Honors Keystone Mercy and AmeriHealth Mercy Health Plans and Tallahassee Memorial HealthCare

(Date:5/18/2013)... , May 18, 2013 Faruqi ... firm, is investigating potential securities fraud at AVEO ... (Logo: http://photos.prnewswire.com/prnh/20120119/MM38856LOGO ) ... and its executives violated federal securities laws by ... Company,s Phase III drug trials for Tivopath (tivozanib) ...

(Date:5/17/2013)... , May 17, 2013 Orexigen® Therapeutics, Inc. (Nasdaq: ... company overview at the UBS Global Healthcare Conference in ... Wednesday, May 22 nd at 11 a.m. Eastern Time. ... the presentation, please visit the Investor Relations section of the ... be available for 14 days after the event. ...

(Date:5/17/2013)... YORK , May 17, 2013 /PRNewswire-iReach/ -- United ... Advanced Cardiac Life Support (ACLS), Pediatric Advanced Life Support ... free PALS, BLS and ACLS online course ... manuals, people simply need to build an account with ... materials for these programs, United Medical Education is setting ...

Breaking Medicine Technology:Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm 2 ACLS Online Course Manuals are Now Available at No Cost through United Medical Education 2

[0] Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In AVEO Pharmaceuticals, Inc. To Contact The Firm [0] Orexigen Therapeutics to Present at the UBS Global Healthcare Conference [0] ACLS Online Course Manuals are Now Available at No Cost through United Medical Education

... BETHESDA, Md., April 14 Micromet, Inc.,(Nasdaq: ... novel, proprietary,antibodies for the treatment of cancer, ... meeting of the American Association for,Cancer Research ... that commercial,anti-cancer antibodies trastuzumab (Herceptin(R); Genentech, Roche),cetuximab ...

... the, Tumor Suppressor P53 Inhibited Tumor Growth Synergistically in Preclinical ... ... 14 ,Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) announced today that ... 2008 Annual Meeting of the American Association for Cancer Research,(AACR) further ...

Cached Medicine Technology:Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 2 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 3 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 4 Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies 5 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 2 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 3 Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies 4

Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies Preclinical Study Presented at AACR Annual Meeting Shows Broad Anti-Cancer Potential of Peregrine's anti-PS Vascular Targeting Antibodies

Touch-Trol Pediatric Suction Catheter Mini-Tray...

SAFE-T-VAC Suction Catheter Kits with Protective Sleeve...

Our suction kits include a Tri-Flo® suction catheter, a pop-up solution basin and two sturdy, precuffed latex exam gloves in an inner wallet. Infant and pediatric kits (5/6, 8 and 10 Fr) feature ...

... kit includes a Tri-Flo® suction ... for flushing and lubrication, two ... inner wallet and a rigid ... (5/6, 8 and 10 Fr) ...

Medicine Products:

Touch-Trol Suction Pediatric Catheter Mini-Tray SAFE-T-VAC Suction Catheter Kits with Protective Sleeve AirLife™ Brand Cath-N-Glove® Suction Kits In Peel Pouch Rigid Suction Tray Kits With Saline